DT
Roche Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Gantenerumab | Alzheimer's Disease | Phase III |
| Cobas MPX-E Assay | Donor Screening (HIV, Hepatitis B/C/E) | Launched |
| Tiragolumab + Tecentriq | Non-Small Cell Lung Cancer (NSCLC) | Phase III |
| Glofitamab | Relapsed/Refractory DLBCL | Approved |
| Mosunetuzumab | Follicular Lymphoma | Approved |
| Vabysmo (Faricimab) | nAMD, Diabetic Macular Edema | Approved |
| Evrysdi (Risdiplam) | Spinal Muscular Atrophy | Approved |
| Poseido (RO7435846) | Huntington's Disease | Phase III |
Leadership Team at Roche
TS
Thomas Schinecker
Chief Executive Officer (CEO)
DA
Dr. Alan Hippe
Chief Financial Officer (CFO)
MS
Matt Sause
Head of Roche Diagnostics
DA
Dr. Aviv Regev
Head of Genentech Research and Early Development (gRED)
DH
Dr. Hans Clevers
Head of Pharma Research and Early Development (pRED)
DC
Dr. Christoph Franz
Chairman of the Board of Directors